Journey Medical Corporation
DERMJourney Medical Corporation in brief
Journey Medical Corporation is a listed company in the Biotechnology industry, based in Scottsdale, Arizona, USA. Its market value was $187 M on 5 October 2026, which makes it the 16,509th largest listed company in the world and the 3,193rd largest in the USA on this site. In the year to December 2025 it had sales of $62 M and a net loss of $11 M. It employs about 58 people and Claude Maraoui is its chief executive. Its largest product and service lines by sales in 2025 were Qbrexza (40%), Emrosi (24%) and Accutane (21%). Its shares trade under the symbol DERM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Journey Medical Corporation
We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc..
From the company's annual report filed with the US SEC: read the report
Journey Medical Corporation timeline
- 2021
- 🔔· approximateInitial public offering on Nasdaq
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2023
- 💰Record revenue of $79 millionFY2023, the highest of the 6 years on record.
Events of Journey Medical Corporation from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,261 (Dec 2022) · #4,970 (Jul 2023) · #3,752 (Jan 2024) · #1,590 (Mar 2026) · #3,133 (Aug 2026) · #3,213 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 2.7×
- Price / book
- 5.9×
- Free cash flow yield
- -12.9%
- Net margin (TTM)
- -7.3%
- Operating margin
- -13.2%
- Return on equity
- -16.0%
- Liabilities / assets
- 66.3%
- Net debt
- $1M
- Revenue growth
- +10.2%
- R&D / revenue
- 0.8%
- Revenue per employee
- $1.1 M
- Profit per employee
- $-197 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $62M | +10.2% | $-8M | $-11M | -18.5% |
| Dec 2024 | $56M | -29.1% | $-14M | $-15M | -26.1% |
| Dec 2023 | $79M | +7.5% | $-2M | $-4M | -4.9% |
| Dec 2022 | $74M | +16.7% | $-28M | $-30M | -40.2% |
| Dec 2021 | $63M | +41.8% | $-35M | $-44M | -69.7% |
| Dec 2020 | $45M | — | $8M | $5M | 11.9% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-12M | — | — | $-0.47 | — |
| Dec 2024 | $-9M | $15M | $-24M | $-0.72 | — |
| Dec 2023 | $5M | $5M | $0M | $-0.21 | — |
| Dec 2022 | $-14M | $20M | $-34M | $-1.69 | — |
| Dec 2021 | $-2M | — | — | $-4.32 | — |
| Dec 2020 | $5M | — | — | $0.49 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (+7.6% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 26, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 30, 2026DEF 14AProxy statement
- Apr 21, 20268-KCurrent reportOther events
- Mar 26, 202610-KAnnual report · period to Dec 2025
- Mar 25, 20268-KCurrent reportResults of operations
- Nov 12, 202510-QQuarterly report · period to Sep 2025
Official filings of Journey Medical Corporation with the US Securities and Exchange Commission.
Annual results
- Revenue
- $62 M
- Operating income
- $-8 M
- Net income
- $-11 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $95 M
- Total liabilities
- $63 M
- Total equity
- $32 M
As of December-2025
Top 74 institutional investors in Journey Medical Corporation#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Wasatch Advisors LP | 2,449,253 | -409,677 (-14.33%) | 8.98% | $17 M | Oct 13, 2026 |
| 2 | Tang Capital Management LLC | 1,610,000 | 0 (0.00%) | 5.90% | $11 M | Nov 16, 2026 |
| 3 | Punch & Associates Investment Management, Inc. | 858,082 | +322,082 (+60.09%) | 3.15% | $6 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 675,185 | 0 (0.00%) | 2.48% | $5 M | Nov 13, 2026 |
| 5 | Pale Fire Capital SE | 521,841 | -6,743 (-1.28%) | 1.91% | $4 M | Nov 13, 2026 |
| 6 | First Eagle Investment Management, LLC | 483,207 | New | 1.77% | $3 M | Nov 10, 2026 |
| 7 | Summit Financial, LLC | 344,214 | -2,534 (-0.73%) | 1.26% | $2 M | Nov 12, 2026 |
| 8 | Diametric Capital, LP | 284,448 | -11,215 (-3.79%) | 1.04% | $2 M | Nov 16, 2026 |
| 9 | Ikarian Capital, LLC | 251,436 | 0 (0.00%) | 0.92% | $2 M | Nov 16, 2026 |
| 10 | Two Sigma Investments, LP | 240,817 | New | 0.88% | $2 M | Nov 16, 2026 |
| 11 | Millennium Management LLC | 239,696 | +129,680 (+117.87%) | 0.88% | $2 M | Nov 16, 2026 |
| 12 | Renaissance Technologies LLC | 228,900 | -800 (-0.35%) | 0.84% | $2 M | Nov 12, 2026 |
| 13 | Geode Capital Management, LLC | 202,066 | -13,938 (-6.45%) | 0.74% | $1 M | Nov 6, 2026 |
| 14 | Marshall Wace, LLP | 194,311 | +54,468 (+38.95%) | 0.71% | $1 M | Nov 13, 2026 |
| 15 | American Financial Group Inc | 180,000 | 0 (0.00%) | 0.66% | $1 M | Nov 12, 2026 |
| 16 | UBS Group AG | 160,066 | +76,552 (+91.66%) | 0.59% | $1 M | Nov 10, 2026 |
| 17 | Opaleye Management Inc. | 125,000 | -225,000 (-64.29%) | 0.46% | $1 M | Nov 16, 2026 |
| 18 | Morgan Stanley | 122,073 | +80,049 (+190.48%) | 0.45% | $1 M | Nov 13, 2026 |
| 19 | Trexquant Investment LP | 121,154 | -50,184 (-29.29%) | 0.44% | $1 M | Nov 16, 2026 |
| 20 | Jane Street Group, LLC | 118,576 | -201,445 (-62.95%) | 0.43% | $1 M | Nov 12, 2026 |
| 21 | Squarepoint Ops LLC | 103,899 | +58,494 (+128.83%) | 0.38% | $1 M | Nov 9, 2026 |
| 22 | BlackRock, Inc. | 96,189 | -4,792 (-4.75%) | 0.35% | $1 M | Nov 13, 2026 |
| 23 | Vanguard Fiduciary Trust Co | 94,729 | 0 (0.00%) | 0.35% | $1 M | Nov 13, 2026 |
| 24 | Goldman Sachs Group Inc | 84,894 | -5,400 (-5.98%) | 0.31% | $1 M | Nov 16, 2026 |
| 25 | PVG Asset Management Corp | 79,573 | 0 (0.00%) | 0.29% | $1 M | Oct 19, 2026 |
Show all 74: investors 26 to 74
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | State Street Corp | 70,578 | +4,600 (+6.97%) | 0.26% | $0 M | Nov 12, 2026 |
| 27 | Boothbay Fund Management, LLC | 67,442 | 0 (0.00%) | 0.25% | $0 M | Nov 16, 2026 |
| 28 | XTX Topco Ltd | 67,163 | -33,760 (-33.45%) | 0.25% | $0 M | Nov 16, 2026 |
| 29 | Geneos Wealth Management Inc. | 63,280 | 0 (0.00%) | 0.23% | $0 M | Nov 9, 2026 |
| 30 | J. Goldman & Co LP | 56,655 | -80,929 (-58.82%) | 0.21% | $0 M | Nov 16, 2026 |
| 31 | Envestnet Asset Management Inc | 54,435 | -11,390 (-17.30%) | 0.20% | $0 M | Nov 16, 2026 |
| 32 | Citadel Advisors LLC | 51,464 | -30,685 (-37.35%) | 0.19% | $0 M | Nov 16, 2026 |
| 33 | Frec Markets, Inc. | 50,500 | 0 (0.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 34 | HRT Financial LP | 45,292 | New | 0.17% | $0 M | Nov 13, 2026 |
| 35 | Integrated Wealth Concepts LLC | 39,750 | +172 (+0.43%) | 0.15% | $0 M | Nov 17, 2026 |
| 36 | ADAR1 Capital Management, LLC | 39,517 | 0 (0.00%) | 0.14% | $0 M | Nov 16, 2026 |
| 37 | Northern Trust Corp | 35,656 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 38 | Salem Investment Counselors Inc | 35,319 | +6,119 (+20.96%) | 0.13% | $0 M | Oct 13, 2026 |
| 39 | Susquehanna International Group, LLP | 30,724 | +10,723 (+53.61%) | 0.11% | $0 M | Nov 16, 2026 |
| 40 | Qube Research & Technologies Ltd | 29,735 | New | 0.11% | $0 M | Nov 13, 2026 |
| 41 | Schonfeld Strategic Advisors LLC | 27,787 | New | 0.10% | $0 M | Nov 16, 2026 |
| 42 | Walleye Capital LLC | 24,720 | -40,742 (-62.24%) | 0.09% | $0 M | Nov 13, 2026 |
| 43 | Prelude Capital Management, LLC | 20,548 | -1,357 (-6.19%) | 0.08% | $0 M | Nov 16, 2026 |
| 44 | Gladstone Institutional Advisory LLC | 20,000 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 45 | Focus Partners Wealth | 19,392 | New | 0.07% | $0 M | Nov 12, 2026 |
| 46 | Bank Of America Corp /de/ | 18,788 | -23,119 (-55.17%) | 0.07% | $0 M | Nov 16, 2026 |
| 47 | Invesco Ltd. | 16,187 | -492 (-2.95%) | 0.06% | $0 M | Nov 12, 2026 |
| 48 | Jefferies Financial Group Inc. | 15,500 | -1,097 (-6.61%) | 0.06% | $0 M | Nov 5, 2026 |
| 49 | Jain Global LLC | 15,463 | New | 0.06% | $0 M | Nov 16, 2026 |
| 50 | Axq Capital, LP | 14,973 | New | 0.05% | $0 M | Nov 12, 2026 |
| 51 | Mariner, LLC | 14,771 | +1,423 (+10.66%) | 0.05% | $0 M | Nov 12, 2026 |
| 52 | BNP Paribas Financial Markets | 14,629 | -32,782 (-69.14%) | 0.05% | $0 M | Nov 12, 2026 |
| 53 | D. E. Shaw & Co., Inc. | 12,785 | New | 0.05% | $0 M | Nov 16, 2026 |
| 54 | Brighton Jones LLC | 12,380 | -322 (-2.54%) | 0.05% | $0 M | Nov 3, 2026 |
| 55 | Jump Financial, LLC | 11,872 | New | 0.04% | $0 M | Nov 13, 2026 |
| 56 | Arrowstreet Capital, Limited Partnership | 11,305 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 57 | Citigroup Inc | 10,881 | +6,810 (+167.28%) | 0.04% | $0 M | Nov 4, 2026 |
| 58 | Atria Investments, Inc | 10,729 | -1,212 (-10.15%) | 0.04% | $0 M | Oct 15, 2026 |
| 59 | Allegiance Financial Group Advisory Services LLC | 10,000 | New | 0.04% | $0 M | Nov 2, 2026 |
| 60 | Persistent Asset Partners Ltd | 9,185 | -897 (-8.90%) | 0.03% | $0 M | Nov 13, 2026 |
| 61 | Barclays PLC | 8,691 | +6,367 (+273.97%) | 0.03% | $0 M | Nov 6, 2026 |
| 62 | Osaic Holdings, Inc. | 8,517 | -485 (-5.39%) | 0.03% | $0 M | Nov 12, 2026 |
| 63 | Royal Bank Of Canada | 8,274 | -680 (-7.59%) | 0.03% | $0 M | Nov 16, 2026 |
| 64 | Jpmorgan Chase & Co | 5,502 | +5,208 (+1771.43%) | 0.02% | $0 M | Nov 12, 2026 |
| 65 | Vanguard Global Advisers, LLC | 4,642 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 66 | Tower Research Capital LLC (TRC) | 2,960 | -2,929 (-49.74%) | 0.01% | $0 M | Nov 16, 2026 |
| 67 | Nuveen, LLC | 2,870 | New | 0.01% | $0 M | Nov 10, 2026 |
| 68 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,345 | New | 0.00% | $0 M | Nov 16, 2026 |
| 69 | PNC Financial Services Group, Inc. | 887 | -381 (-30.05%) | 0.00% | $0 M | Nov 6, 2026 |
| 70 | Simplex Trading, LLC | 621 | New | 0.00% | $0 M | Nov 4, 2026 |
| 71 | Jones Financial Companies Lllp | 570 | New | 0.00% | $0 M | Nov 13, 2026 |
| 72 | Russell Investments Group, Ltd. | 465 | +216 (+86.75%) | 0.00% | $0 M | Nov 6, 2026 |
| 73 | FMR LLC | 376 | -100 (-21.01%) | 0.00% | $0 M | Nov 10, 2026 |
| 74 | Caitong International Asset Management Co., Ltd | 20 | +9 (+81.82%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Journey Medical Corporation#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Wasatch Micro Cap FundWasatch Advisors LP | 1.30 M | $9 M | 4.3% | 1.4% | +58% | Jun 30, 2026 |
| 🇺🇸 Wasatch Micro Cap Value FundWasatch Advisors LP | 788,173 | $6 M | 2.6% | 1.4% | +9.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 470,426 | $3 M | 1.6% | <0.01% | −44% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 186,966 | $1 M | 0.62% | <0.01% | −19% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 105,535 | $1 M | 0.35% | <0.01% | +48% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 104,017 | $1 M | 0.35% | <0.01% | +45% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 50,931 | $0 M | 0.17% | 0.02% | −1.2% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 41,381 | $0 M | 0.14% | <0.01% | +76% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 28,610 | $0 M | 0.10% | <0.01% | +53% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 19,126 | $0 M | 0.06% | <0.01% | +45% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 14,064 | $0 M | 0.05% | <0.01% | +62% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 10,418 | $0 M | 0.03% | <0.01% | −1.2% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 8,545 | $0 M | 0.03% | <0.01% | +73% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 7,375 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 3,597 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,380 | $0 M | 0.01% | 0.01% | −4.2% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 3,125 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,559 | $0 M | <0.01% | <0.01% | −30% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 1,406 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 973 | $0 M | <0.01% | <0.01% | +56% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 760 | $0 M | <0.01% | <0.01% | −15% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 766 | $0 M | <0.01% | <0.01% | −14% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 298 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 117 | $0 M | <0.01% | <0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 79 | $0 M | <0.01% | <0.01% | −27% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 25 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Journey Medical Corporation#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Miranda Jayne ToledanoDirector | Grant or award | +50,000 | — | — | 168,618 | Form 4 |
| filed | Justin Adam SmithDirector | Grant or award | +50,000 | — | — | 231,618 | Form 4 |
| filed | Neil HerskowitzDirector | Grant or award | +50,000 | — | — | 168,618 | Form 4 |
| filed | Miranda Jayne ToledanoDirector | Grant or award | +10,000 | — | — | 118,618 | Form 4 |
| filed | Justin Adam SmithDirector | Grant or award | +10,000 | — | — | 181,618 | Form 4 |
| filed | Neil HerskowitzDirector | Grant or award | +10,000 | — | — | 118,618 | Form 4 |
| filed | Michael Cooper PearceDirector | Grant or award | +10,000 | — | — | 67,173 | Form 4 |
| filed | Lindsay A. RosenwaldDirector | Grant or award | +10,000 | — | — | 221,146 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Journey Medical Corporation#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-05-15 13:35 UTC, code LUDP, resumed 13:40 UTC
Fails to deliver
- : 579 shares at $6.61
- : 110 shares at $6.72
- : 16,031 shares at $6.32
- : 200 shares at $7.29
- : 476 shares at $7.38
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Journey Medical Corporation scorecard#
Passes 7 of the 22 checks that could be worked out: strongest in profitability (2 of 5), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 5, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median5.9×Price to book 5.9× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median2.7×Price to sales 2.7× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-12.9%Free cash flow is -12.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 6
- ✓Revenue grew in the newest year10.2%Revenue up 10.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-5.7%-5.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-5.7%-5.7% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.47 vs -0.72Diluted EPS -0.47 in fiscal 2025 against -0.72 the year before (report's currency).
- ✗Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against $5 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-13.2%-13.2% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-44.0%-44.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-13.2%-13.2% in fiscal 2025 against -37.4% in 2022.
Financial health2 of 5
- ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.79 at the end of fiscal 2025.
- ✓Debt below equity0.8×Debt to equity 0.79 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-2.2×Operating income -2.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.07Z-score 1.07 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year19.9%Diluted shares up 19.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Journey Medical Corporation's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -13.2% | -60.5% | |
| Net margin | -18.5% | -68.9% | |
| Return on equity | -44.0% | -61.0% | |
| Revenue growth, 3 years a year | -5.7% | 12.9% | |
| Revenue growth | 10.2% | 15.8% | |
| Debt to equity | 0.79× | 0.26× |
4of 9on the Piotroski tests of financial strength
- Net loss of $11 million, the 5th loss-making year in a row.
- The share count rose 19.9% in the year.
- Operating income covers the interest bill only -2.2 times.
- Receivables grew 191% while revenue grew 10%: customers are paying later, or sales were booked ahead of cash.
Journey Medical Corporation: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 62+10.2%100% | 56−29.1%100% | 79+7.5%100% | 74+16.7%100% | 63+41.8%100% | 45—100% | |
| Cost of revenue | 21+0.2%33.8% | 21−8.8%37.2% | 23r27−25.6%28.9% | 31−4.1%41.8% | 32+120%50.8% | 15—32.8% | |
| Research and development | 0.5−95.1%0.8% | 9.9+30.7%17.6% | 7.5−31.1%9.5% | 11+300%14.9% | 2.7—4.3% | — | |
| Selling, general and administrative | 44+10.4%71.7% | 40−8.4%71.6% | 44−26.2%55.5% | 59+49.3%80.7% | 40+80.4%63.1% | 22—49.6% | |
| Total costs and expenses | 70+0.3%113% | 70−14.1%124% | 81−19.7%103% | 101+3.2%137% | 98+167%155% | 37—82.4% | |
| Operating income | −8.2—−13.2% | −14—−24.4% | −2.1—−2.6% | −28—−37.4% | −35−544%−55.2% | 7.9—17.6% | |
| Interest expense and finance costs | 3.7+37.0%6.0% | 2.7+59.0%4.8% | 1.7−15.9%2.1% | 2.0−71.3%2.7% | 7.0+908%11.1% | 0.7—1.6% | |
| Other non-operating income (expense) | −3.2—−5.2% | −0.9—−1.7% | −1.6—−2.0% | −2.0—−2.8% | −7.5—−11.8% | −0.7—−1.6% | |
| Income before tax | −11—−18.4% | −15—−26.0% | −3.6—−4.6% | −30—−40.1% | −42−692%−67.1% | 7.2—16.1% | |
| Income tax | 0.1−1.6%0.1% | 0.1−72.4%0.1% | 0.2+251%0.3% | 0.1−96.1%0.1% | 1.6−12.6%2.6% | 1.9—4.2% | |
| Net income including minority interests | −11—−18.5% | −15—−26.1% | −3.9—−4.9% | −30—−40.2% | −44−933%−69.7% | 5.3—11.9% | |
| Net income attributable to shareholders | −11—−18.5% | −15—−26.1% | −3.9—−4.9% | −30—−40.2% | −44−933%−69.7% | 5.3—11.9% | |
| Earnings per share, basic | -0.47—— | -0.72—— | -0.21—— | -1.69—— | -4.32−845%— | 0.58—— | |
| Earnings per share, diluted | -0.47—— | -0.72—— | -0.21—— | -1.69—— | -4.32−982%— | 0.49—— | |
| Shares, weighted average (basic) | 24+19.9%— | 20+12.1%— | 18+4.0%— | 18+72.0%— | 10+11.5%— | 9.1—— | |
| Shares, weighted average (diluted) | 24+19.9%— | 20+12.1%— | 18+4.0%— | 18+72.0%— | 10−6.0%— | 11—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 24+18.6%25.5% | 20−26.0%25.3% | 27−14.3%35.7% | 32−34.8%30.4% | 49+495%50.5% | 8.2—15.9% | |
| Receivables | 30+191%31.5% | 10−32.8%12.8% | 15−46.0%19.8% | 28+22.0%26.8% | 23−3.4%23.8% | 24—46.1% | |
| Inventory | 9.6−33.3%10.2% | 14+41.4%18.0% | 10−27.9%13.3% | 14+43.6%13.5% | 9.9+602%10.1% | 1.4—2.7% | |
| Other current assets | 3.4+5.1%3.6% | 3.2−10.5%4.0% | 3.6+8.4%4.7% | 3.3+35.7%3.1% | 2.4+46.5%2.5% | 1.7—3.2% | |
| Current assets | 67+38.8%70.7% | 48−14.7%60.0% | 56−27.3%73.5% | 78−8.1%73.9% | 84+140%86.9% | 35—67.9% | |
| Right-of-use (leased) assets | 0.1−44.2%0.1% | 0.2+97.0%0.2% | 0.1−46.6%0.1% | 0.2+112%0.2% | 0.1−49.1%0.1% | 0.2—0.3% | |
| Other intangible assets | 28−13.4%29.2% | 32+57.1%39.7% | 20−25.4%26.4% | 27+117%25.9% | 13−16.5%12.9% | 15—29.0% | |
| Total assets | 95+17.9%100% | 80+4.4%100% | 77−26.9%100% | 105+8.1%100% | 97+87.4%100% | 52—100% | |
| Accounts payable | 8.9−44.9%9.4% | 16−11.6%20.0% | 18−50.4%23.6% | 37+60.3%34.8% | 23+1140%23.4% | 1.8—3.5% | |
| Current liabilities | 37+6.4%39.6% | 35−16.0%43.8% | 42−37.4%54.5% | 67+29.5%63.6% | 52r52+83.9%53.1% | 28—54.1% | |
| Long-term debt | 25+1.6%26.7% | 25+70.1%31.0% | 15−26.2%19.0% | 20—18.9% | — | — | |
| Lease liabilities (non-current) | 0.0−84.7%0.0% | 0.1+1211%0.1% | 0.0−91.7%0.0% | 0.1—0.1% | — | 0.1—0.2% | |
| Total liabilities | 63+4.3%66.3% | 60+6.5%75.0% | 56−35.9%73.5% | 88+59.6%83.9% | 55+32.7%56.8% | 42—80.2% | |
| Retained earnings | −98—−104% | −87—−108% | −72—−94.2% | −69—−65.1% | −39−859%−40.0% | 5.1—9.9% | |
| Shareholders' equity | 32+58.7%33.7% | 20−1.4%25.0% | 20+19.8%26.5% | 17−59.6%16.1% | 42+309%43.2% | 10—19.8% | |
| Total liabilities and equity | 95+17.9%100% | 80+4.4%100% | 77−26.9%100% | 105+8.1%100% | 97+87.4%100% | 52—100% | |
| Shares outstanding | — | — | — | — | 11+259%— | 3.2—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | — | — | — | — | 0−100%0.0% | 0.0—0.0% | |
| Share-based compensation | 6.3+3.1%10.2% | 6.1+134%10.9% | 2.6−41.1%3.3% | 4.4+79.4%6.0% | 2.5+1512%3.9% | 0.2—0.3% | |
| Cash from operating activities | −12—−20.1% | −9.1−274%−16.3% | 5.2—6.6% | −14—−18.4% | −2.2−142%−3.5% | 5.1—11.5% | |
| Capital expenditure | — | −15—−26.7% | −5.0—−6.3% | −20—−27.1% | — | — | |
| Intangible assets bought | — | — | — | — | −10—−15.8% | −1.2—−2.7% | |
| Cash from investing activities | — | −15—−26.7% | −5.0—−6.3% | −20—−27.1% | −10—−15.8% | −1.2—−2.7% | |
| Shares issued | 16+108%26.4% | 7.9+75.3%14.0% | 4.5—5.7% | — | 33—51.5% | — | |
| Cash from financing activities | 16−4.5%26.2% | 17—30.3% | −4.8−129%−6.1% | 16−69.0%22.3% | 53—84.0% | −0.5—−1.1% | |
| Change in cash | 3.8—6.1% | −7.1—−12.7% | −4.6—−5.8% | −17−142%−23.2% | 41+1085%64.7% | 3.4—7.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 70+17.0%100% | 19+7.6%100% | 19+23.3%100% | 16+21.5%100% | 16*+18.1%100% | 18+20.5%100% | 15+1.0%100% | 13+0.8%100% | 14*−10.7%100% | 15—100% | 15—100% | 13—100% | 15*—100% | |
| Cost of revenue | 24+33.7%34.1% | 5.9+2.2%31.0% | 6.1+24.4%33.2% | 6.2+29.8%39.0% | 5.4*+143%33.8% | 5.8+8.9%32.6% | 4.9−24.5%32.9% | 4.8−29.7%36.5% | 2.2*−0.5%16.4% | 5.3—36.1% | 6.5—44.0% | 6.8—52.3% | 2.2r6.0*—14.7% | |
| Research and development | — | 0.1−82.2%0.3% | 0.1—0.3% | — | 0.2*−29.4%1.0% | 0.3−65.9%1.6% | 0*−100%0.0% | 0.0−99.5%0.3% | 0.2*−85.5%1.6% | 0.8—5.8% | 0.9—6.1% | 7.9—60.5% | 1.5*—9.9% | |
| Selling, general and administrative | 43−2.5%62.5% | 13+4.5%66.4% | 11−8.4%58.8% | 10−4.4%63.3% | 9.9*−2.0%61.3% | 12+5.8%68.4% | 12+15.0%79.2% | 11+25.5%80.4% | 10*+2.2%73.9% | 11—77.9% | 10—69.5% | 8.4—64.6% | 9.8*—64.5% | |
| Total costs and expenses | 72+10.2%103% | 19+1.8%103% | 18+0.9%97.5% | 17+6.0%109% | 17*+45.1%103% | 19+9.3%109% | 18+0.6%119% | 16−28.8%125% | 11*−34.4%83.6% | 18—120% | 18—120% | 23—177% | 17*—114% | |
| Operating income | −2.0—−2.9% | −0.5—−2.8% | 0.5—2.5% | −1.5—−9.3% | −0.4*−120%−2.8% | −1.5—−8.7% | −2.9—−19.2% | −3.3—−25.3% | 2.2*—16.4% | −2.9—−19.8% | −2.9—−19.7% | −10—−77.4% | −2.1*—−13.8% | |
| Interest expense and finance costs | 3.7+1.5%5.3% | 0.9−1.9%4.8% | 0.9−3.3%4.9% | 0.9+0.1%5.6% | 0.9*+12.3%5.8% | 0.9+23.6%5.3% | 0.9+66.4%6.2% | 0.9+62.6%6.8% | 0.8*+3363%6.1% | 0.8—5.2% | 0.6—3.8% | 0.5—4.2% | 0.0*—0.2% | |
| Other non-operating income (expense) | −3.1—−4.4% | −0.8—−4.1% | −0.8—−4.1% | −0.7—−4.6% | −0.8*—−5.0% | −0.8−256%−4.5% | −0.9—−5.7% | −0.7—−5.7% | −0.7*−849%−4.8% | 0.5—3.4% | −0.4—−2.9% | −0.4—−2.7% | 0.1*—0.6% | |
| Income before tax | −5.1—−7.3% | −1.3—−6.9% | −0.3—−1.6% | −2.2—−14.0% | −1.2*−179%−7.8% | −2.3—−13.1% | −3.7—−24.9% | −4.1—−31.0% | 1.6*—11.6% | −2.4—−16.3% | −3.4—−22.6% | −10—−80.1% | −2.0*—−13.2% | |
| Income tax | — | 0—0.0% | 0.0−75.0%0.1% | — | 0*—0.0% | 0*—0.0% | 0.1—0.4% | — | — | — | — | — | 0.1*—0.8% | |
| Net income including minority interests | −5.1—−7.3% | −1.3*—−6.9% | −0.3*—−1.7% | −2.2—−14.0% | −1.2*−182%−7.8% | −2.3*—−13.1% | −3.8*—−25.3% | −4.1—−31.0% | 1.5*—11.2% | −2.4*—−16.3% | −3.4*—−22.6% | −10—−80.1% | −2.1*—−14.0% | |
| Net income attributable to shareholders | −5.1—−7.3% | −1.3—−6.9% | −0.3—−1.7% | −2.2—−14.0% | −1.2*−182%−7.8% | −2.3—−13.1% | −3.8—−25.3% | −4.1—−31.0% | 1.5*—11.2% | −2.4—−16.3% | −3.4—−22.6% | −10—−80.1% | −2.1*—−14.0% | |
| Earnings per share, basic | — | -0.05—— | -0.01—— | -0.08—— | — | -0.09—— | -0.16—— | -0.18—— | — | -0.12—— | -0.17—— | -0.53—— | — | |
| Earnings per share, diluted | — | -0.05—— | -0.01—— | -0.08—— | — | -0.09—— | -0.16—— | -0.18—— | — | -0.12—— | -0.17—— | -0.53—— | — | |
| Shares, weighted average (basic) | 28+12.5%— | 28+12.5%— | 27+18.0%— | 27+20.8%— | — | 25+21.5%— | 23+16.5%— | 23+14.4%— | — | 21—— | 20—— | 20—— | — | |
| Shares, weighted average (diluted) | 28+12.5%— | 28+12.5%— | 27+18.0%— | 27+20.8%— | — | 25+21.5%— | 23+16.5%— | 23+14.4%— | — | 21—— | 20—— | 20—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 22—21.5% | 22−10.5%21.5% | 26+26.4%26.1% | 27+29.2%29.7% | 24+18.6%25.5% | 25+11.1%29.3% | 20−15.1%25.0% | 21−12.4%24.8% | 20−26.0%25.3% | 22—35.1% | 24—36.7% | 24—36.1% | 27—35.7% | |
| Receivables | 47—45.6% | 47+164%45.6% | 36+132%36.9% | 25+38.7%27.3% | 30+191%31.5% | 18+68.5%21.1% | 16+49.5%19.3% | 18+83.9%21.2% | 10−32.8%12.8% | 11—16.7% | 10—16.1% | 9.8—14.7% | 15—19.8% | |
| Inventory | 7.8—7.5% | 7.8−34.2%7.5% | 8.2−36.5%8.3% | 9.3−25.6%10.2% | 9.6−33.3%10.2% | 12+0.3%13.9% | 13+32.7%15.8% | 12+18.1%14.7% | 14+41.4%18.0% | 12—18.4% | 9.7—14.9% | 11—15.9% | 10—13.3% | |
| Other current assets | 1.8—1.7% | 1.8+8.8%1.7% | 2.7+10.4%2.8% | 3.5+44.6%3.8% | 3.4+5.1%3.6% | 1.6+31.9%1.9% | 2.5+3.0%3.1% | 2.4−7.1%2.8% | 3.2−10.5%4.0% | 1.2—1.9% | 2.4—3.7% | 2.6—3.9% | 3.6—4.7% | |
| Current assets | 79—76.3% | 79+40.6%76.3% | 73+42.0%74.0% | 65+20.3%71.0% | 67+38.8%70.7% | 56+22.2%66.2% | 51+10.3%63.2% | 54+14.8%63.5% | 48−14.7%60.0% | 46—72.1% | 46—71.3% | 47—70.6% | 56—73.5% | |
| Right-of-use (leased) assets | 0.0—0.0% | 0.0−69.4%0.0% | 0.1−58.3%0.1% | 0.1−50.6%0.1% | 0.1−44.2%0.1% | 0.1+319%0.2% | 0.2+184%0.2% | 0.2+125%0.2% | 0.2+97.0%0.2% | 0.0—0.0% | 0.1—0.1% | 0.1—0.1% | 0.1—0.1% | |
| Other intangible assets | 25—23.6% | 25−14.4%23.6% | 26−14.2%25.9% | 26−14.0%28.9% | 28−13.4%29.2% | 29+60.7%33.7% | 30+59.4%36.6% | 31+58.2%36.2% | 32+57.1%39.7% | 18—27.9% | 19—28.6% | 19—29.3% | 20—26.4% | |
| Total assets | 104—100% | 104+21.9%100% | 98+21.2%100% | 92+7.7%100% | 95+17.9%100% | 85+33.0%100% | 81+24.5%100% | 85+27.6%100% | 80+4.4%100% | 64—100% | 65—100% | 67—100% | 77—100% | |
| Accounts payable | 9.4—9.0% | 9.4−18.7%9.0% | 8.0−36.9%8.2% | 8.2−43.1%9.0% | 8.9−44.9%9.4% | 12−24.7%13.6% | 13−12.7%15.7% | 14−6.1%17.0% | 16−11.6%20.0% | 15—24.0% | 15—22.4% | 15—23.0% | 18—23.6% | |
| Debt due within a year | 7.5—7.2% | 7.5+33.3%7.2% | 5.0+33.3%5.1% | 2.5+33.3%2.7% | — | 5.6—6.6% | 3.8—4.6% | 1.9—2.2% | — | — | — | — | — | |
| Current liabilities | 54—51.5% | 54+34.8%51.5% | 46+13.1%46.5% | 38−5.9%41.3% | 37+6.4%39.6% | 40+19.1%46.6% | 40+18.6%49.9% | 40+3.3%47.3% | 35−16.0%43.8% | 33—52.0% | 34—52.4% | 39—58.5% | 42—54.5% | |
| Long-term debt | 18—17.4% | 18−7.5%17.4% | 20−4.2%20.8% | 23−1.0%25.0% | 25+1.6%26.7% | 20−1.3%22.9% | 21+8.2%26.3% | 23+57.3%27.2% | 25+70.1%31.0% | 20—30.9% | 20—30.3% | 15—22.1% | 15—19.0% | |
| Lease liabilities (non-current) | — | — | — | — | 0.0−84.7%0.0% | 0.0—0.1% | 0.1—0.1% | 0.1—0.1% | 0.1+1211%0.1% | — | — | — | 0.0—0.0% | |
| Total liabilities | 72—68.9% | 72+20.8%68.9% | 66+7.0%67.3% | 61−4.3%66.3% | 63+4.3%66.3% | 59+11.6%69.6% | 62+14.9%76.3% | 63+18.3%74.6% | 60+6.5%75.0% | 53—82.9% | 54—82.7% | 54—80.5% | 56—73.5% | |
| Retained earnings | −102—−98.5% | −102—−98.5% | −101—−103% | −101—−110% | −98—−104% | −97—−114% | −95—−117% | −91—−107% | −87—−108% | −89—−138% | −86—−132% | −83—−124% | −72—−94.2% | |
| Shareholders' equity | 32—31.1% | 32+24.5%31.1% | 32+66.9%32.7% | 31+43.1%33.7% | 32+58.7%33.7% | 26+137%30.4% | 19+70.4%23.7% | 22+66.3%25.4% | 20−1.4%25.0% | 11—17.1% | 11—17.3% | 13—19.5% | 20—26.5% | |
| Total liabilities and equity | 104—100% | 104+21.9%100% | 98+21.2%100% | 92+7.7%100% | 95+17.9%100% | 85+33.0%100% | 81+24.5%100% | 85+27.6%100% | 80+4.4%100% | 64—100% | 65—100% | 67—100% | 77—100% | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5.5−6.1%8.0% | 1.3−28.1%7.0% | 1.4+7.6%7.8% | 1.0−25.2%6.2% | 1.8*+28.8%11.0% | 1.9+13.0%10.5% | 1.3−20.2%8.9% | 1.3−5.9%10.1% | 1.4*+160%10.1% | 1.6—11.2% | 1.7—11.3% | 1.4—10.8% | 0.5*—3.5% | |
| Cash from operating activities | −8.5—−12.3% | −3.4*—−18.1% | −1.7*—−9.4% | 2.9—18.2% | −6.3*−382%−39.1% | −2.4*—−13.5% | −0.9*—−6.3% | −2.8—−21.6% | 2.2*—16.3% | −1.2*—−7.9% | −5.2*—−34.8% | −5.0—−38.5% | −17*—−108% | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Shares issued | — | — | — | — | 5.4*−12.6%33.7% | 6.9*+3452%39.1% | 0*—0.0% | 4.0+173%30.8% | 6.2*—45.5% | 0.2*—1.3% | 0*—0.0% | 1.5—11.4% | — | |
| Cash from financing activities | 5.9−72.4%8.5% | 0.1*−98.3%0.6% | 0.2*−4.2%0.9% | 0.2−93.9%1.4% | 5.4*−48.9%33.7% | 7.0*—39.9% | 0.2*−96.7%1.1% | 3.6+120%27.4% | 11*−44.7%78.0% | −0.3*—−2.0% | 5.0*—33.9% | 1.6—12.6% | 19*—126% | |
| Change in cash | −2.6−206%−3.8% | −3.3*−171%−17.5% | −1.6*—−8.5% | 3.1+309%19.6% | −0.9*—−5.3% | 4.7*—26.4% | −0.8*—−5.2% | 0.8—5.8% | −2.2*−180%−15.8% | −1.5*—−9.9% | −0.1*—−1.0% | −3.4—−26.0% | 2.7*—17.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Journey Medical Corporation sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Qbrexza$25 M40%-0.4%
- Emrosi$15 M24%—
- Accutane$13 M21%-34%
- Foam franchise products (Amzeeq & Zilxi)$6 M9.5%-12%
- Other / legacy$3 M4.4%-31%
Business segments
- Dermatological segment$62 M100%+10%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Journey Medical Corporation#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 3 · Agreement ended 1 · New debt 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementNew debt | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $19 M | No. 1 | $10 to $50 million | 146 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Journey Medical Corporation#
1 labor condition applications certified in fiscal 2023 for 1 positions, at a median wage of $180 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Director – Regulatory Affairs & QualityRegulatory Affairs Managers | 1 | $180 K |
Where: Scottsdale, AZ 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Journey Medical Corporation
How Journey Medical Corporation compares in Biotechnology
- Market cap$187 M · higher than 43% of 726
- Revenue$62 M · higher than 62% of 647
- Net margin-7.3% · higher than 66% of 408
- Revenue growth10.2% · higher than 53% of 438
- Price / sales2.7× · lower than 80% of 339
- Price / book5.9× · lower than 26% of 534
- FCF yield-12.9% · higher than 52% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Journey Medical Corporation🇺🇸 | $187 M | — | -7.3% | +10.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 5, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 18, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Journey Medical Corporation? Verify and update this profile — free
Show Journey Medical Corporation's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.